

Paul Chipperton, BSc, MBA

E: pchipperton@hotmail.com

T: +1 647 291 8545

Profile

Award-winning serial entrepreneur & CEO in the Healthcare sector, cumulatively raised >C\$30M, and with 2xFDA clearances (+1 pending 2026). Co-founder & CEO of Profound Medical (NASDAQ: prof). Deeply experienced Board Chair & member, including Angel Investors Ontario (AIO). Reviewer and strategic consultant to Canadian Provincial and Federal government health innovation initiatives. Single-term Senator to Queen's University Senate. Part-time master's lecturer to Queen's, McMaster and University of Toronto.

Experience-Commercial

AllStent Inc.

Jul 2024 — Present

CEO & co-founder, BOD

- Founded company with R&D personnel and IP from Politecnico di Milano, Italy
- Raised initial C\$225,000 investment from US UC Berkeley Skydeck Program May-2025
- Populated CAB with global thought leaders in TEVAR vascular surgeries
- Leading negotiations with both "Top-4" Stent manufacturers and possible SW partners

Insight Medbotics Inc.

Apr 2021 — Jun 2023

CEO & President, BOD

- Raised >C\$2M from McMaster Innovation Seed fund, MDA (tsx:mda), and Angels
- Led Strategy, financing, planning of MR-guided robotic breast biopsy technology with space engineering company MDA Inc (tsx:mda)
- Successful submittal and receipt of US FDA 510k class II clearance

EiGR Consulting & Advisory

Jan 2012 — Present

Managing Director

- Angel Investors Ontario –Board of Directors (2017-2023)
- Eastern Health, NL, Strategic Innovation Advisor (2019-2023)
- Mperia Therapeutics Inc. -Board of Directors (2018-2019)
- SWFTCharge Inc. –Board of Directors (2017-2019)
- Intronix Inc. –Board of Directors (2015-2019)
- CanFocus Technologies Inc. –interim-CEO
- Ontario Centres of Innovation (OCI) – "SmartStart" commercialization program reviewer
- Adjuvant Therapeutics Inc. –Private oncology medical device firm, Business plan mandate

PROFOUND MEDICAL Inc. (nasdaq: prof)
CEO, Co-founder & Board of Directors

June 2008 — May 2012

- Founded, then hired and managed entrepreneurial company of 20 personnel
- Sourced and recruited eminent Board of Director (BOD) and Clinical Advisory Board (CAB) personnel from Cleveland Clinic, Harvard/MGH, and University of Vienna
- Individually managed Investor Relations and secured >\$16M of cash over 3.5 years
- Designed company, clinical and regulatory strategy for FDA Class III, PMA-path device
- Executed all BD work, including securing SiemensAG as strategic clinical trial partner
- Negotiated Research & Development agreements with plethora of internationally recognized clinical cancer treatment entities, including UWO (Canada), DKFZ (Germany), Cleveland Clinic Foundation-CCF (USA)
- Built brand and corporate presence to national industry- and peer-reviewed award wins

Matrogen Corp.
VP-Business Development (Acting-CEO)

October 2004 — March 2008

- Led all Corporate Development and Investor Relations activities, including presentation, negotiation, and closure of C\$ 1M venture capital investment round

NorthStar Technology Consulting
Co-founder & Managing Director

June 2002 — September 2004

- CGI Inc.- Consultant to Life Science Service Centre (LS2C) on strategic development. Recommended merger with CGI's pharmaceutical MRP business unit. Merger was successfully executed
- DNA Genotek Inc.- Co-authored Business Plan and valuation for 1st round-funding of novel DNA collection and purification technology. Presenter to Angel investor community

Education

- **McGill University-MBA** , Concentrations in Strategy & Marketing 2002 — 2004
- **Northumbria University-BSc**, Applied Chemistry 1989 — 1993
- Northeastern University-Cert. Cannabis Regulatory Landscape 2019
- Osgoode Law School, York Univ.-Cert. Blockchain & the Law 2019

Awards

- 2010 Ontario Premier's Catalyst Award for "Start-up Company with Best Innovation." \$200,000 prize
- 2009 OCRI "Top 10 Canadian Life Science Companies"

Experience-Public & Private Boards

| | |
|--|----------------------|
| Vectorialis Inc.: Board Member | Jul 2025 - Current |
| OPP Detachment Board: Earlton Board Member | Nov 2024 – Dec 2025 |
| Insight Medbotics Inc.: CEO & President, Board Member | Apr 2021 — Jun 2023 |
| Northeastern University (Boston): MSc Regul. Program Advisory Cmte. | Jun 2019 – Feb 2024 |
| LSK Technologies Inc.: Chair of Board & Member | Mar 2020 – Jun 2023 |
| Angel Investors Ontario: Board Member, Chair of Marketing Cmte. | Nov 2017 — Oct 2023 |
| SWFTCharge Inc.: Co-founder & Board member | Jun 2017 — Feb 2019 |
| Queen’s University Senate: Senator | Sept 2016 – Aug 2017 |
| Intronix Inc.: Chair of Board | Feb 2015 – May 2019 |
| CanFocus Inc.: Co-founder & Chair of Board | May 2012 – Oct 2013 |
| Queen’s University: Scholarship & Student Aid Cmte. | Sept 2013 – Aug 2015 |
| Profound Medical Inc.: CEO & co-founder, Board Member | Jun 2008 – May 2012 |

Experience-Academic

Vienna University of Economics & Business-WU Dec 2018 — Present
Lecturer, International School of Management

- MBA/MIB course instructor “*Strategic Innovation & Entrepreneurship*”

Politecnico di Milano Jan 2021 — Present
Visiting Lecturer, Chemistry, Materials & Chemical Engineering

- MBioMEng course instructor, “*Business Fundamentals for Biomedical Engineering*”

Queen’s University Mar 2012 — Present
Adjunct Lecturer & Senator, Smith School of Business

- Senator, Queen’s University, 2016-2017
- *Frank Know Teaching Award*, Honorary Mention, 2017-2018
- AMBA course instructor, MBUS806 “*Strategic Innovation & Entrepreneurship*”
- MBA course instructor, MBAS841 “*New Venture Management*”

University of Toronto Dec 2019 — Present
Lecturer, Institute for Management & Innovation

- MBIO course instructor, BTC2030 “*Mgmt. of Technological Innovation*”
- MHSc course instructor, LMP2300 “*Foundations of Translational Research*”

McMaster University Sep 2020—Present
Lecturer, W Booth School of Engineering Practice & Technology

- BIOMEDIN 712: Navigating Complexity in Healthcare
- MEEI/MTEI course instructor, SEP755 “*Business Launch & Development*”